Home » Newsletters » BioWorld

BioWorld

April 4, 2006

View Archived Issues

Veronate Data Crush Inhibitex; Drug's Future Cast Into Doubt

Shares in Inhibitex Inc. plunged by two-thirds Monday after the company released poor Phase III data on Veronate. (BioWorld Today) Read More

Sirna, GSK Enter Respiratory Deal Worth Up To $700M-Plus

Cancer Drug Developers Running Out Of Excuses

FDA Holds Up Cortex's CX717; Incyte Scratching DFC For HIV

EPIX Buying Predix For $90M, With $35M Milestone Potential

Merrimack's Series E: $65M For Autoimmune, Oncology

Other News To Note

Appointments And Advancements

Clinic Roundup

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...